Advanced Phase I/II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Gemcitabine-resistant Metastatic Pancreatic Cancer

Rexin-G, a nonreplicative pathology-targeted retroviral vector bearing a cytocidal cyclin G1 construct, was tested in a phase I/II study for gemcitabine-resistant pancreatic cancer. The patients received escalating doses of Rexin-G intravenously from 1 × 10(11) colony-forming units (cfu) 2–3× a week...

Descripción completa

Detalles Bibliográficos
Autores principales: Chawla, Sant P, Chua, Victoria S, Fernandez, Lita, Quon, Dorris, Blackwelder, William C, Gordon, Erlinda M, Hall, Frederick L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2839309/
https://www.ncbi.nlm.nih.gov/pubmed/19826403
http://dx.doi.org/10.1038/mt.2009.228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2839309/
https://www.ncbi.nlm.nih.gov/pubmed/19826403
http://dx.doi.org/10.1038/mt.2009.228

Ejemplares similares